Anokion Announces KAN-101 Phase 1 Success & Phase 2 Plans
Anokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.
Continue ReadingAnokion SA announced successful completion of its Phase 1 clinical trial evaluating KAN-101 for the treatment of celiac disease, with promising results.
Continue ReadingThe FDA hosted the Gastroenterology Regulatory Endpoints and the Advancement of Therapeutics VI (GREAT VI) Workshop on Celiac Disease - the second workshop ever held by the FDA for celiac disease.
Continue ReadingThe overall prevalence of celiac disease was found to be 1.6% - a much greater percentage than the 1% that researchers have been approximating for years.
Continue ReadingFor the second consecutive year, the Celiac Disease Foundation hosted the Patient Education & Advocacy Summit.
Continue ReadingThe Celiac Disease Genomic Environmental Microbiome and Metabolomic (CDGEMM) study is revealing how genetic and lifestyle factors make children susceptible to autoimmune diseases such as celiac disease, inflammatory bowel disease, and multiple sclerosis.
Continue ReadingInitial findings of the first mass screening study for U.S. children show a high prevalence of celiac disease autoimmunity (CDA) among those without symptoms and no family history of the condition.
Continue ReadingThe Senate Appropriations Committee has released their FY2021 funding recommendations, which includes report language directing NIH to support celiac disease research.
Continue ReadingA new Alcohol and Tobacco Tax and Trade Bureau (TTB) ruling released October 13 allows a gluten-free label on spirits distilled from gluten-containing grains.
Continue ReadingThe first study of its kind in North America has found an increased risk for birth defects in children of women with active, untreated celiac disease.
Continue ReadingThe Celiac Disease Foundation is proud to partner with Mediaplanet for their Morning Nutrition campaign.
Continue Reading